How to Validate a Drug Target Before Committing to a Programme

Four questions, each with a stopping rule:

The third question is often answered last and should be answered early: a validated target with no modality is a biology paper, not a programme.

Direction matters more than strength. A strong association with the opposite direction from your intended pharmacology is worse than a weak association in the right direction.

Human genetics is not optional. Targets with genetic support have historically had higher approval success; the absence of genetic support is a risk factor, not a disqualifier.

Perturbation must mimic the drug. An inhibitor reduces activity; a knockout removes protein. Where the mechanism is inhibition, an inducible knockdown or a catalytically dead knock-in is closer evidence than a null allele.

Disease-relevant model before commitment, not after. The most common expensive mistake is a programme that reaches candidate selection with only immortalized-line data.

For a target with existing genetic support:

1. Week 1–2: confirm expression and pathway state in two disease-relevant cell models.
2. Week 2–4: knockout or inducible knockdown; measure the phenotype; include rescue.
3. Week 4–5: dose–response using graded knockdown, to estimate the therapeutic window.
4. Week 5–6: chemical or genetic modality feasibility check, including a resistance-mutation strategy if a small molecule is planned.

That package does not prove the target will work; it establishes whether the next twelve months are justified.

EDITGENE builds the evidence for the middle two questions: knockout, inducible knockdown and rescue derivatives, dose–response panels, and disease-relevant models with the readouts that field expects.

Tell us the target and the stage. Contact EDITGENE to request a project consultation or quote.

Target validation reduces risk; it does not predict clinical efficacy. Decisions should weigh the evidence against the modality and the disease.

Associations and cellular phenotypes are context-specific and should be reported with the model and perturbation used.

• • Nelson MR, et al. The support of human genetic evidence for approved drug indications. Nature Genetics. 2015;47:856–860.
• • Plenge RM, et al. Validating therapeutic targets through human genetics. Nature Reviews Drug Discovery. 2013;12:581–594.
• • Bunnage ME, et al. Target validation using chemical probes. Nature Chemical Biology. 2013;9:195–199.